

Deep sea water improves hypercholesterolemia and hepatic lipid accumulation through the regulation of hepatic lipid metabolic gene expression

KYU-SHIK LEE, SO-YOUNG CHUN, YUN-SUK KWON, SOYOUNG KIM and KYUNG-SOO NAM

Department of Pharmacology and Intractable Disease Research Center, School of Medicine,
Dongguk University, Gyeongju, Gyeongsangbuk-do 38066, Republic of Korea

Received March 16, 2016; Accepted January 6, 2017

DOI: 10.3892/mmr.2017.6317

Abstract. A high-fat diet or high-cholesterol diet (HCD) is a major cause of metabolic diseases, including obesity and diabetes; vascular diseases, including hypertension, stroke and arteriosclerosis; and liver diseases, including hepatic steatosis and cirrhosis. The present study aimed to evaluate the effects of deep sea water (DSW) on rats fed a HCD. DSW decreased HCD-induced increases in total cholesterol and low-density lipoprotein (LDL) cholesterol in the blood, and recovered high-density lipoprotein cholesterol. In addition, DSW decreased levels of liver injury markers, which were increased in response to HCD, including glutamate-oxaloacetate transaminase, glutamate-pyruvate transferase and alkaline phosphatase. Lower lipid droplet levels were observed in the livers of rats fed a HCD and treated with DSW at a hardness of 1,500, as compared with those in the HCD only group. Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) revealed that mRNA expression levels of fatty acid synthase and sterol regulatory element binding protein-1c (SREBP-1c) in rats fed a HCD with DSW were lower compared with the HCD only group. Furthermore, quantitative RT-PCR revealed that DSW enhanced LDL receptor (LDLR) mRNA expression in a hardness-dependent manner. Combined, the results of the present study indicated that DSW may reduce HCD-induced increases in blood and liver lipid levels, indicating that DSW may protect against hypercholesterolemia and non-alcoholic hepatic steatosis. In addition, the present study demonstrated that DSW-induced downregulation of lipids in the blood and hepatic lipid accumulation was

mediated by enhancement of LDLR expression and suppression of fatty acid synthase and SREBP-1c.

Introduction

Hyperlipidemia is a lipid metabolism disorder, the prevalence of which has markedly increased in recent years. This disorder, which is caused by excessive consumption of food containing high levels of fat and cholesterol, is closely associated with hypertension, atherosclerosis (AS) and cardiovascular diseases (CVD) (1-3). It has previously been established that circulating low-density lipoprotein cholesterol (LDL-c), total cholesterol (TC) and triglycerides (TGs) are important risk factors in hypertension, AS and CVD (4-6). Increased levels of LDL-c, TC and TG in the blood weaken vessel walls and subsequently block blood flow, which may lead to myocardial infarction and stroke. Hypercholesterolemia may also be coupled with hepatic lipid accumulation. Increased lipid content in the liver induces chronic inflammation, which accelerates liver injury and may result in cirrhosis, liver failure and cancer. Accordingly, downregulation of increased LDL-c, TC and TG is required to prevent and treat these vascular and hepatic diseases.

It is well established that amelioration of lipid concentration in the blood prevents hypercholesterolemia and hepatic lipid accumulation. Lipid metabolism in the liver is controlled by fatty acid-synthesizing and energy expenditure enzymes, with decreased energy expenditure enzymes and increased fatty acid-synthesizing enzymes generally being observed in the livers of obese animal models fed a high-fat diet (HFD) and/or a high-cholesterol diet (HCD) (2,7-9). Furthermore, the hepatic expression levels of LDL receptor (LDLR) are associated with the concentration of circulating serum cholesterol in experimental animals fed a HFD and/or HCD (10). Previous studies have demonstrated that numerous candidates are able to decrease blood LDL-c, TC and TG levels via the suppression of lipogenic factors and the induction of lipolytic factors in obese animals, and several candidates improved lipid components in the blood via regulation of LDLR expression in hyperlipidemic rodents (2,7,9,11). These results indicated that regulation of lipid metabolism enzymes and LDLR are useful strategies for preventing liver fat accumulation and hypercholesterolemia.

Correspondence to: Professor Kyung-Soo Nam, Department of Pharmacology and Intractable Disease Research Center, School of Medicine, Dongguk University, 123 Dongdae-ro, Gyeongju, Gyeongsangbuk-do 38066, Republic of Korea
E-mail: namks@dongguk.ac.kr

Key words: deep sea water, hypercholesterolemia, hepatic lipid accumulation, low-density lipoprotein receptor, lipid metabolic gene

Deep sea water (DSW) is considered a potent material that has food and medical applications. DSW contains abundant minerals, including magnesium (Mg), calcium (Ca), potassium (K) and zinc, which have important roles in cellular homeostasis and physiological responses (12-24). The beneficial effects of DSW on vascular diseases and metabolic disorders have been well demonstrated and these effects are thought to be associated with lipid metabolism (19,20). Hwang *et al* (19) demonstrated that DSW decreased body weight and improved lipid components in *ob/ob* mice; in addition, the differentiation of 3T3-L1 adipocytes was prevented by DSW (19,20). Although the beneficial effects of DSW in lipid metabolism have previously been investigated in several laboratories, the preventative effects of DSW on liver fat accumulation and hypercholesterolemia have not been fully investigated. Therefore, the present study aimed to determine the effects of DSW on liver fat accumulation and hypercholesterolemia in rats fed a HCD.

Materials and methods

Preparation of DSW. DSW was obtained from the Marine Deep Ocean Water Application Research Center in the Korea Institute of Ocean Science & Technology (Ansan, South Korea) from a depth of 500 m in the East Sea (Goseong, South Korea). Saline and minerals in DSW were removed and extracted by reverse osmosis filtration and electrodialysis (16). Extracted minerals were dissolved in desalinated DSW to generate hardness 4,000 (H4000) DSW containing 835.6 mg/l Mg, 279.9 mg/l Ca, 213.7 mg/l Na and 81.2 mg/l K (Mg:Ca concentration ratio, 3:1). H4000 DSW was serially diluted with desalinated DSW to prepare DSW of various hardness (400-2,000). The hardness of DSW was determined by the following formula: Total hardness=Ca hardness [2.5 x Ca concentration (mg/l)] + Mg hardness [4.1 x Mg concentration (mg/l)].

Animals and treatment. Animal experiments were conducted following approval by the Animal Use and Care Committee at Dongguk University (approval IACUC-2013-001; Gyeongju, Korea). A total of 42 male 5-week old Sprague-Dawley rats (120-130 g) with a normal diet (ND; 5L57, containing no cholesterol) were obtained from Orient Bio Inc. (Seongnam, Korea). The rats were housed under a 12 h light/dark cycle at 25±2°C and a relative humidity of 50±5%. The rats received the ND and tap water *ad libitum* for 1 week. Subsequently, rats received a HCD (D12336, Research Diets, Inc., New Brunswick, NJ, USA) with tap water or DSW of various hardness *ad libitum* for 6 weeks. The composition of the HCD is presented in Table I. Rats were randomly divided into 1 ND group and 6 experimental groups: Tap HCD, H0 HCD, H400 HCD, H800 HCD, H1500 HCD and H2000 HCD. Each group consisted of 6 rats. Body weight, and food and water intake were measured every 2-3 days during the experiment. After 6 weeks, animals were fasted for 24 h and subsequently sacrificed with ether by inhalation, then blood was collected to determine the lipid composition in each group.

Analysis of blood lipid components. TG, TC and high-density lipoprotein cholesterol (HDL-c) in the blood were enzymatically analyzed using commercial kits (AM157K, AM202K

Table I. Composition of high-cholesterol diet.

Ingredient	Amount (g/kg)
Casein	75
Soy protein	130
DL-methionine	2
Corn starch	275
Maltodextrin 10	150
Sucrose	30
Cellulose	90
Soy bean	50
Cocoa butter	75
Coconut oil	35
Mineral mix	35
Calcium carbonate	5.5
Sodium chloride	8
Potassium citrate	10
Vitamin mix V10001	10
Choline bitartrate	2
Cholesterol	12.5
Sodium cholic acid	5
Total calories (cal/kg)=4,128. (D12336; Research Diets, Inc., New Brunswick, NJ, USA).	

and AM203K respectively; Asan Pharmaceutical Co., Ltd., Seoul, Korea) according to the manufacturer's protocols. The LDL-c concentration was calculated using the Friedwald formula: LDL-c concentration=TC concentration-HDL-c concentration-TG/2.

Evaluation of liver damage indicators. Glutamate-oxaloacetate transaminase (GOT), glutamate-pyruvate transferase (GPT) and alkaline phosphatase (ALP) activity in the blood were assessed as indicators of liver damage. GOT and GPT activities were measured using a commercial kit (AM101K; Asan Pharmaceutical Co., Ltd.) based on the Reitman-Frankel method (25), whereas ALP activity was determined using a Kind-King method-based commercial kit (AM105S; Asan Pharmaceutical Co., Ltd.) according to the manufacturer's protocols.

Electron microscopic analysis. Livers were pre-fixed with 0.1 M PBS containing 2.5% glutaraldehyde for 2 h at 4°C and subsequently washed with 0.1 M PBS three times for 15 min. The tissues were subsequently post-fixed by immersion in 2% osmium tetroxide solution for 2 h at 4°C followed by dehydration with ethanol. Tissues were embedded with epon-812 resin, sectioned at 100 nm thickness using a Leica Ultracut R (Leica Microsystems GmbH, Wetzlar, Germany) and double-stained with uranyl acetate and lead nitrate. Finally, tissues were visualized using a Hitachi H-7500 transmission electron microscope (Hitachi, Ltd., Tokyo, Japan) at 80 kV.

Semi-quantitative and quantitative (q) reverse transcription-polymerase chain reaction (RT-PCR). The expression of fatty acid synthase (FAS), carnitine palmitoyltransferase-1 (CPT-1),

Table II. Sequences of primers used for semi-quantitative RT-PCR and RT-qPCR.

A, Semi-quantitative PCR				
Gene	F/R primer	Primer sequence	Annealing temperature (°C)	Cycle number
FAS	F	5'-CTGGACTCGCTCATGGGTG-3'	60	25
	R	5'-CATTTCTGAAGCTTCCGCAG-3'		
CPT-1	F	5'-AACCTTGGCTGCGGTAAGACTA-3'	60	22
	R	5'-AGTGGGACATTCTCTCTCAGG-3'		
SREBP-1c	F	5'-GATGCCAACCCAGATTCCCTAAG-3'	60	29
	R	5'-TCAGTTGTTTCTTTGCCTTCCA-3'		
PPAR γ	F	5'-TTCAGTTTGGAGACTTCGGACC-3'	60	32
	R	5'-TAGGCTCCTGCCAGATTACTCC-3'		
GAPDH	F	5'-AACTTTGGCATCGTGGAAGG-3'	59	22
	R	5'-TACATTGGGGGTAGGAACAC-3'		
B, RT-qPCR				
Gene	F/R primer	Primer sequence	Annealing temperature (°C)	Cycle number
LDLR	F	5'-CAGCTCTGTGTGAACCTGGA-3'	58	45
	R	5'-TTCTTCAGGTTGGGGATCAG-3'		
GAPDH	F	5'-AACTTTGGCATCGTGGAAGG-3'	58	45
	R	5'-TACATTGGGGGTAGGAACAC-3'		

RT-PCR, reverse transcription-polymerase chain reaction; RT-qPCR, quantitative RT-PCR; F, forward; R, reverse; FAS, fatty acid synthase; CPT-1, carnitine palmitoyltransferase-1; SREBP-1c, sterol regulatory element binding protein-1c; PPAR γ , peroxisome proliferator-activated receptor γ ; LDLR, LDL receptor.

sterol regulatory element binding protein-1c (SREBP-1c) and peroxisome proliferator-activated receptor γ (PPAR γ) was analyzed by semi-quantitative RT-PCR, and qPCR was used to analyze the expression of LDLR. Livers were rapidly frozen in liquid nitrogen and stored at -80°C. Total RNA in individual liver samples was extracted using an easy-BLUE™ Total RNA Extraction kit (17061; Intron Biotechnology, Inc., Seongnam, Korea) according to the manufacturer's protocol. cDNA synthesis was performed using PrimeScript™ 1st strand cDNA Synthesis kit (6110a; Takara Bio, Inc., Otsu, Japan) according to the manufacturer's protocols and amplification of PCR products for semi-quantitative RT-PCR was performed with 2 μ l of cDNA in *Ex Taq* DNA polymerase mixture containing 2 mM MgCl₂, 200 μ M dNTP (Takara Bio, Inc.) and 0.2 μ M of each forward and reverse primer (Bioneer Corporation, Daejeon, Korea) with a final reaction volume of 25 μ l. The PCR cycling conditions were as follows: 95°C for 10 min (initial denaturation), 22-32 cycles at 95°C for 30 sec, 60°C for 30 sec, 72°C for 30 sec (amplification) and 72°C for 10 min (final extension). All reactions were finished during the exponential phases. PCR products and 100 bp ladder (WelGene Co., Daegu, Korea) were subjected to agarose gel electrophoresis containing 0.5 μ g/ml ethidium bromide (Promega Corporation, Madison, WI, USA) and observed using i-MAX Gel Image Analysis System with CoreBio MFC software (CoreBio System Co., Ltd., Seoul, Korea). qPCR was performed using a QGreen™ SYBR Green Master Mix

kit (Cellsafe Co. Ltd., Suwon, Korea) and the Eco Real-Time PCR system (Illumina, Inc., San Diego, CA, USA). The PCR cycling conditions were as follows: 95°C for 10 min followed by 45 cycles at 95°C for 10 sec, 60°C for 10 sec and 72°C for 30 sec. The relative intensity of the target genes was calculated using Eco™ software version 3.1.7 (Illumina, Inc., San Diego, CA, USA) by the $\Delta\Delta$ Cq method (26). GAPDH was used as an internal control to normalize target gene expression. The PCR primer sequences for target genes are presented in Table II.

Statistical analysis. Values were presented as the mean \pm standard deviation. Statistical analysis was performed using one-way analysis of variance with SPSS software (version no. 22; SPSS, Inc., Chicago, IL, USA) followed by Student's *t*-test. *P*<0.05 was considered to indicate a statistically significant difference.

Results

Changes in the lipid composition of blood in response to DSW treatment. The present study monitored body weight, and food and water (tap water or DSW) intake, in rats fed a HCD. No significant differences in body weight (Fig. 1A) or food intake (Fig. 1B) were observed among the groups. However, reduced total water intake was observed in DSW groups in a hardness-dependent manner (Fig. 1C). In addition, blood lipid components were measured. Blood TC and LDL-c in rats fed




Figure 1. Effects of DSW on body weight, and total food and water intake, in rats fed a HCD. (A) Body weight of each rat was measured every 2-3 days. Values are presented as the mean \pm standard deviation, $n=6$. (B) Total food intake and (C) total tap water or DSW intake, was measured every 2-3 days. Values are presented as the sum of the amount of food, and volume of water, consumed in each group for 6 weeks. DSW, deep sea water; HCD, high-cholesterol diet; Tap, tap water; H, hardness.

a HCD were increased ~ 3.4 - and 29.9 -fold, respectively, and HDL-c was decreased ~ 4.8 -fold compared with rats fed a ND (data not shown). Despite the decreased total water intake in DSW groups, significantly reduced levels of TC and LDL-c were observed in the H800 ($P<0.05$) and H1500 ($P<0.01$) HCD groups compared with the Tap HCD group (Fig. 2A and B). In addition, significantly increased HDL-c was detected in response to DSW in the H800 and H1500 HCD groups compared with in the Tap HCD group ($P<0.05$; Fig. 2C). However, no significant alterations in TG were observed among the groups (Fig. 2D).

Suppression of hepatic lipid accumulation. Metabolic diseases, including obesity, diabetes and hypercholesterolemia, may be induced by a HCD and are associated with hepatic lipid accumulation (27). Therefore, the present study analyzed the distribution of lipid droplets in rat liver cells using electron microscopy. The liver cells of rats fed a HCD exhibited numerous lipid droplets and the number of lipid droplets was visibly increased in HCD livers compared with ND-fed rat livers. However, the H1500 DSW HCD group exhibited fewer liver cell lipid droplets compared with the Tap HCD group (Fig. 3). Conversely, the H2000 group exhibited increased numbers of lipid droplets in liver cells compared

with the H1500 DSW HCD group (Fig. 3). The results of electron microscopy corresponded to the blood TC, LDL-c and HDL-c levels observed in these groups.

Alleviation of liver injury indices. Lipid accumulation in the liver, and increased blood TC and LDL-c concentration, are associated with liver injury. The present study detected the suppressive effects of DSW on hepatic lipid accumulation, and the elevation of blood TC and LDL-c concentration. Therefore, the effects of DSW on liver injury indices in the blood, including GOT, GPT and ALP, were assessed. HCD-induced increased GOT, GPT and ALP levels in the blood were significantly decreased by H1500 DSW compared with the Tap HCD group ($P<0.05$; Fig. 4); however, H2000 DSW did not significantly reduce levels compared with the Tap HCD group (Fig. 4). The decrease in GOT, GPT and ALP levels corresponded with the decrease of hepatic lipid accumulation and blood TC and LDL-c levels.

Regulation of lipid metabolism-regulating gene expression in the liver. Lipid homeostasis in the liver is governed by the balance of expression between fatty acid-synthesizing enzymes and energy expenditure enzymes. Numerous studies




Figure 2. Effects of DSW on levels of serum lipid components. Serum (A) TC, (B) LDL-c, (C) HDL-c and (D) TG concentrations were measured in rats fed a HCD with tap water or DSW of various hardness for 6 weeks. Values are presented as the mean \pm standard deviation, $n=6$. * $P < 0.05$ and ** $P < 0.01$ vs. the Tap HCD group. DSW, deep sea water; TC, total cholesterol; LDL-c, low-density lipoprotein cholesterol; HDL c, high-density lipoprotein cholesterol; TG, triglyceride; HCD, high-cholesterol diet; Tap, tap water; H, hardness.




Figure 3. Effects of DSW on lipid accumulation in the liver. Lipid droplets in the liver were observed by electron microscopy. Arrows indicate lipid droplets. Representative images (magnification, $\times 2,000$) from five independent experiments are presented. DSW, deep sea water; Tap, tap water; ND, normal diet; H, hardness; HCD, high-cholesterol diet.

have detected fat accumulation in the livers of HFD- and/or HCD-fed rodents (7,8,28). Furthermore, hepatic FAS, PPAR γ and SREBP-1c expression in rodent livers have previously been demonstrated to be significantly increased by a HFD

and/or HCD (8,11,16,28,29). Therefore, the present study investigated the difference in the expression of these genes between control and DSW groups in rats fed a HCD. In addition, the expression of CPT-1, an energy expenditure enzyme,




Figure 4. Effects of DSW on liver injury indicators. Serum (A) GOT (B) GPT and (C) ALP activities were measured in rats fed a HCD with tap water or DSW of various hardness for 6 weeks. Values are presented as the mean \pm standard deviation, $n=6$. * $P<0.05$ vs. the Tap HCD group. DSW, deep sea water; GOT, glutamate-oxaloacetate transaminase; GPT, glutamate-pyruvate transaminase; ALP, alkaline phosphatase; HCD, high-cholesterol diet; Tap, tap water; H, hardness.

was assessed. DSW groups exhibited significantly reduced levels of FAS and SREBP-1c expression in H800, H1500 and H2000 HCD groups compared with the Tap HCD group ($P<0.05$; Fig. 5A and B). However, no significant differences were observed in CPT-1 and PPAR γ expression (Fig. 5C and D).

Regulation of hepatic LDLR gene expression. The present study demonstrated that serum TC and LDL-c levels were decreased in response to DSW in rats fed a HCD. Circulating serum cholesterol is primarily absorbed in the liver through hepatic LDLR-mediated endocytosis and is subsequently metabolized (30,31). Consequently, serum cholesterol levels should be associated with hepatic LDLR levels. Therefore, the present study investigated mRNA expression of LDLR in the liver of rats. The results revealed a significant increase in hepatic LDLR mRNA in rats fed a HCD in response to DSW at H800 and H1500 compared with the Tap HCD group ($P<0.05$; Fig. 6). However, although H2000 DSW also increased LDLR mRNA expression compared with in the Tap HCD group, the increase was not statistically significant (Fig. 6).

Discussion

Several studies have demonstrated the importance of minerals, including Mg and Ca, in lipid metabolism. For example,

increased Mg intake was demonstrated to prevent hypercholesterolemia, lipid oxidation and oxidative damage (32,33). Conversely, growth inhibition in fetal mice was induced by altered lipid metabolism caused by maternal Mg deficiency and low levels of Mg in blood were observed in obese children from South India (34,35). In addition, a high Ca intake was associated with low serum levels of TC and LDL-c in humans (36). The present study demonstrated that the blood lipid composition in rats fed a HCD improved in response to DSW containing high levels of Mg and Ca (concentration ratio Mg:Ca=3:1; Fig. 2). The results indicated that DSW may reduce blood TC and LDL-c, and increase HDL-c, through increased blood Mg and Ca levels. However, the TC, LDL-c and HDL-c levels in rats treated with H2000 DSW, the highest hardness in this experiment, were not significantly altered (Fig. 2A-C). These results demonstrated that increased Mg levels in the blood may have an important role in the reduction of harmful cholesterol; however, the beneficial effects of excessive concentrations of Mg and Ca may be lower.

Increased levels of blood lipid components, including TG, TC and LDL-c, induced by a HFD and/or HCD may lead to liver fat accumulation. The hepatic accumulation of fat may be prevented by lowering blood levels of these lipid components. Previous studies (19,23,29) have demonstrated that DSW attenuated hepatic lipid accumulation in hamsters and mice.




Figure 5. Effects of DSW on hepatic lipid metabolism-regulating gene expression. Levels of hepatic lipid metabolism-regulating genes (A) FAS, (B) SREBP-1c, (C) CPT-1 and (D) PPAR γ were assessed by semi-quantitative RT-PCR and the densities were normalized to GAPDH, which was used as an internal control. To perform semi-quantitative RT-PCR, an equal amount of six individual total RNA samples in each group were pooled. Values are presented as the mean \pm standard deviation, n=3. *P<0.05 and **P<0.01 vs. the Tap HCD group. DSW, deep sea water; FAS, fatty acid synthase; SREBP-1c, sterol regulatory element binding protein-1c; CPT-1, carnitine palmitoyltransferase-1; PPAR γ , peroxisome proliferator-activated receptor γ ; RT-PCR, reverse transcription-polymerase chain reaction; Tap, tap water; HCD, high-cholesterol diet; H, hardness.




Figure 6. Effects of DSW on hepatic LDLR expression. The relative expression levels of hepatic LDLR were determined by RT-qPCR. To perform RT-qPCR, an equal amount of six individual total RNA samples in each group were pooled. GAPDH was used as an internal control. Values are presented as the mean \pm standard deviation, n=3. *P<0.05 vs. the Tap HCD group. DSW, deep sea water; LDLR, low-density lipoprotein receptor; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; Tap, tap water; HCD, high-cholesterol diet; H, hardness.

Furthermore, an increase of Mg and Ca in DSW led to the alleviation of hepatic lipid accumulation and oxidation in a concentration-dependent manner in hamsters fed HFDs (29). The results of the present study demonstrated that H1500 DSW prevented lipid accumulation in the liver; however, this decrease was not observed in the H2000 DSW group (Fig. 3). Therefore, although the association between hepatic lipid accumulation and mineral (Mg and Ca) content is unclear, the results of the present study indicated that the beneficial effects of DSW on hepatic lipid accumulation may be determined by the concentration of Mg and Ca in DSW.

Increased levels of liver injury indicators are associated with liver fat accumulation and increased serum TC and LDL-c. Chen *et al* (29) detected decreased GOT and GPT in hamsters fed a HFD/HCD for 6 weeks following treatment with DSW drinking water. In addition, the previous study demonstrated that the decrease was associated with a reduction in TC and TG concentration. The results of the present study are consistent with those of Chen *et al* (29; Fig. 4). High levels of GOT, GPT and ALP have been observed in patients with liver

diseases, including hepatitis, cirrhosis, liver failure and liver cancer (37,38). Therefore, the suppression of increases in GOT, GPT and ALP levels may be important for the prevention of diet-induced hepatic diseases.

PPAR γ and SREBP-1c are transcriptional regulators of lipid metabolism enzymes. Previous studies (28,39) have demonstrated that hepatic PPAR γ and SREBP-1c expression were increased in rodents fed a HFD and/or HCD, and that suppression of PPAR γ and SREBP-1c gene expression reduced fat accumulation and blood TC and LDL-c levels in livers of mice. Furthermore, decreased lipid deposits in hepatocytes were observed when SREBP-1c silencing was performed *in vitro* (40). In the present study, DSW suppressed liver fat accumulation and reduced the HCD-induced increases in TC and LDL-c levels in the blood and FAS and SREBP-1c transcription; however, no effects on CPT-1 and PPAR γ expression were observed (Fig. 5). Although Chen *et al* (29) demonstrated that serum lipid component levels were improved in response to DSW drinking water, no effects were observed on FAS and SREBP-1c expression in response to DSW (29). The ratio of Mg:Ca in DSW drinking water in Chen *et al* (29) was 4-5:1; however, DSW in the present investigation was 3:1. Therefore, the dissimilarity in the effects of DSW on FAS and SREBP-1c expression may be caused by differences in the ratio of Mg:Ca. The results of the present study indicated that DSW may prevent lipid accumulation in the liver via suppression of FAS expression regulated by SREBP-1c, without the induction of CPT-1 transcription, and may be more effective at preventing liver fat accumulation and increases in TC and LDL-c levels.

Previous studies (31,41-43) have demonstrated an association between decreasing serum cholesterol and increasing LDLR expression in the liver in response to various materials. The present study demonstrated that H800 and H1500 DSW decreased serum LDL-c concentrations, and that this decrease was accompanied by the induction of LDLR expression in rats fed a HCD (Figs. 2B and 6). Therefore, the present study indicated that the hypocholesterolemic effects of DSW may be mediated by LDLR. However, although decreases in the expression levels of FAS and SREBP-1c were observed (Fig. 5), H2000 DSW did not prevent liver fat accumulation or improve serum lipid component levels (Figs. 2 and 3). In addition, LDLR expression was not significantly increased by H2000 DSW compared with in the Tap HCD group (Fig. 6). Although it is unclear why H2000 DSW does not affect liver fat accumulation, serum TG, TC and LDL-c levels, and hepatic LDLR expression, it may be hypothesized that these effects may be associated with Mg and Ca concentration. Consequently, the results of the present study indicated that H1500 DSW may be most suitable for preventing liver fat accumulation and hypercholesterolemia.

In conclusion, the present study assessed the effects of DSW on HCD-induced hepatic lipid accumulation and hypercholesterolemia in rats. The results demonstrated that DSW decreased TG, TC, LDL-c, GOT, GPT and ALP levels in the blood, and reduced lipid accumulation in the liver. Furthermore, the mRNA expression levels of FAS and SREBP-1c were downregulated, whereas the expression of LDLR was upregulated by DSW. Combined, these results indicated that DSW may have the potential to prevent hepatic lipid accumulation and may exert blood cholesterol-lowering activity via the inhibition of fatty acid synthesis in the liver and enhancement of LDL-c clearance

in the blood, caused by increased hepatic LDLR expression. The present study indicated that DSW is a candidate for the prevention of hypercholesterolemia and hepatic lipid accumulation.

Acknowledgements

This work was financially supported by the National R&D Project 'Development of New Application Technology For Deep Sea Water Industry' supported by the Ministry of Oceans and Fisheries of the Republic of Korea.

References

1. Ma Y, Wang W, Zhang J, Lu Y, Wu W, Yan H and Wang Y: Hyperlipidemia and atherosclerotic lesion development in Ldlr-deficient mice on a long-term high-fat diet. *PLoS One* 7: e35835, 2012.
2. Zhang X, Wu C, Wu H, Sheng L, Su Y, Zhang X, Luan H, Sun G, Sun X, Tian Y, *et al*: Anti-hyperlipidemic effects and potential mechanisms of action of the caffeoylquinic acid-rich Pandanus tectorius fruit extract in hamsters fed a high fat-diet. *PLoS One* 8: e61922, 2013.
3. Daniels SR: Management of hyperlipidemia in pediatrics. *Curr Opin Cardiol* 27: 92-97, 2012.
4. Cholesterol Treatment Trialists' (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, *et al*: Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet* 376: 1670-1681, 2010.
5. Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, Greenland P, Van Horn L, Tracy RP and Lloyd-Jones DM: Lifetime risks of cardiovascular disease. *N Engl J Med* 366: 321-329, 2012.
6. Harchaoui KE, Visser ME, Kastelein JJ, Stroes ES and Dall'Aglio GM: Triglycerides and cardiovascular risk. *Curr Cardiol Rev* 5: 216-222, 2009.
7. Yang ZH, Miyahara H, Takeo J, Hatanaka A and Katayama M: Pollock oil supplementation modulates hyperlipidemia and ameliorates hepatic steatosis in mice fed a high-fat diet. *Lipids Health Dis* 10: 189, 2011.
8. Yao Z, Liu XC and Gu YE: Schisandra chinensis Baill, a Chinese medicinal herb, alleviates high-fat-diet-inducing non-alcoholic steatohepatitis in rats. *Afr J Tradit Complement Altern Med* 11: 222-227, 2013.
9. Carrier B, Wen S, Zigouras S, Browne RW, Li Z, Patel MS, Williamson DL and Rideout TC: Alpha-lipoic acid reduces LDL-particle number and PCSK9 concentrations in high-fat fed obese Zucker rats. *PLoS One* 9: e90863, 2014.
10. Singh AB, Kan CF, Shende V, Dong B and Liu J: A novel post-transcriptional mechanism for dietary cholesterol-mediated suppression of liver LDL receptor expression. *J Lipid Res* 55: 1397-1407, 2014.
11. Kim H, Bartley GE, Arvik T, Lipson R, Nah SY, Seo K and Yokoyama W: Dietary supplementation of chardonnay grape seed flour reduces plasma cholesterol concentration, hepatic steatosis, and abdominal fat content in high-fat diet-induced obese hamsters. *J Agric Food Chem* 62: 1919-1925, 2014.
12. Kim S, Chun SY, Lee DH, Lee KS and Nam KS: Mineral-enriched deep-sea water inhibits the metastatic potential of human breast cancer cell lines. *Int J Oncol* 43: 1691-1700, 2013.
13. Katsuda S, Yasukawa T, Nakagawa K, Miyake M, Yamasaki M, Katahira K, Mohri M, Shimizu T and Hazama A: Deep-sea water improves cardiovascular hemodynamics in Kurosawa and Kusanagi-Hypercholesterolemic (KHC) rabbits. *Biol Pharm Bull* 31: 38-44, 2008.
14. Lee KS, Shin JS, Kwon YS, Moon DS and Nam KS: Suppression of cancer progression and metastasis in HT-29 human colorectal adenocarcinomas by deep sea water. *Biotechnol Bioproc Eng* 18: 194-200, 2013.
15. Fu ZY, Yang FL, Hsu HW and Lu YF: Drinking deep seawater decreases serum total and low-density lipoprotein-cholesterol in hypercholesterolemic subjects. *J Med Food* 15: 535-541, 2012.
16. Ha BG, Shin EJ, Park JE and Shon YH: Anti-diabetic effect of balanced deep-sea water and its mode of action in high-fat diet induced diabetic mice. *Mar Drugs* 11: 4193-4212, 2013.

17. Hataguchi Y, Tai H, Nakajima H and Kimata H: Drinking deep-sea water restores mineral imbalance in atopic eczema/dermatitis syndrome. *Eur J Clin Nutr* 59: 1093-1096, 2005.
18. Hsu CL, Chang YY, Chiu CH, Yang KT, Wang Y, Fu SG and Chen YC: Cardiovascular protection of deep-seawater drinking water in high-fat/cholesterol fed hamsters. *Food Chem* 127: 1146-1152, 2011.
19. Hwang HS, Kim HA, Lee SH and Yun JW: Anti-obesity and anti-diabetic effects of deep sea water on ob/ob mice. *Mar Biotechnol* (NY) 11: 531-539, 2009.
20. Hwang HS, Kim SH, Yoo YG, Chu YS, Shon YH, Nam KS and Yun JW: Inhibitory effect of deep-sea water on differentiation of 3T3-L1 adipocytes. *Mar Biotechnol* (NY) 11: 161-168, 2009.
21. Li PC, Pan CH, Sheu MJ, Wu CC, Ma WF and Wu CH: Deep sea water prevents balloon angioplasty-induced hyperplasia through MMP-2: An in vitro and in vivo study. *PLoS One* 9: e96927, 2014.
22. Miyamura M, Yoshioka S, Hamada A, Takuma D, Yokota J, Kusunose M, Kyotani S, Kawakita H, Odani K, Tsutsui Y and Nishioka Y: Difference between deep seawater and surface seawater in the preventive effect of atherosclerosis. *Biol Pharm Bull* 27: 1784-1787, 2004.
23. Sheu MJ, Chou PY, Lin WH, Pan CH, Chien YC, Chung YL, Liu FC and Wu CH: Deep sea water modulates blood pressure and exhibits hypolipidemic effects via the AMPK-ACC pathway: An in vivo study. *Mar Drugs* 11: 2183-2202, 2013.
24. Yoshioka S, Hamada A, Cui T, Yokota J, Yamamoto S, Kusunose M, Miyamura M, Kyotani S, Kaneda R, Tsutsui Y, *et al*: Pharmacological activity of deep-sea water: Examination of hyperlipemia prevention and medical treatment effect. *Biol Pharm Bull* 26: 1552-1559, 2003.
25. Reitman S and Frankel S: A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. *Am J Clin Pathol* 28: 56-63, 1957.
26. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25: 402-408, 2001.
27. Vuppalanchi R and Chalasani N: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. *Hepatology* 49: 306-317, 2009.
28. Inoue M, Ohtake T, Motomura W, Takahashi N, Hosoki Y, Miyoshi S, Suzuki Y, Saito H, Kohgo Y and Okumura T: Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. *Biochem Biophys Res Commun* 336: 215-222, 2005.
29. Chen IS, Chang YY, Hsu CL, Lin HW, Chang MH, Chen JW, Chen SS and Chen YC: Alleviative effects of deep-seawater drinking water on hepatic lipid accumulation and oxidation induced by a high-fat diet. *J Chin Med Assoc* 76: 95-101, 2013.
30. Ma PT, Gil G, Südhof TC, Bilheimer DW, Goldstein JL and Brown MS: Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. *Proc Natl Acad Sci USA* 83: 8370-8374, 1986.
31. Yasunobu Y, Hayashi K, Shingu T, Nomura K, Ohkura Y, Tanaka K, Kuga Y, Nomura S, Ohtani H, Nishimura T, *et al*: Reduction of plasma cholesterol levels and induction of hepatic LDL receptor by cerivastatin sodium (CAS 143201-11-0, BAY w 6228), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, in dogs. *Cardiovasc Drugs Ther* 11: 567-574, 1997.
32. Abad C, Vargas FR, Zoltan T, Proverbio T, Piñero S, Proverbio F and Marín R: Magnesium sulfate affords protection against oxidative damage during severe preeclampsia. *Placenta* 36: 179-185, 2015.
33. Olatunji LA and Soladoye AO: Increased magnesium intake prevents hyperlipidemia and insulin resistance and reduces lipid peroxidation in fructose-fed rats. *Pathophysiology* 14: 11-15, 2007.
34. Gupta M, Solanki MH, Chatterjee PK, Xue X, Roman A, Desai N, Rochelson B and Metz CN: Maternal magnesium deficiency in mice leads to maternal metabolic dysfunction and altered lipid metabolism with fetal growth restriction. *Mol Med* 20: 332-340, 2014.
35. Niranjana G, Anitha D, Srinivasan AR, Velu VK, Venkatesh C, Babu MS, Ramesh R and Saha S: Association of inflammatory sialoproteins, lipid peroxides and serum magnesium levels with cardiometabolic risk factors in obese children of South Indian population. *Int J Biomed Sci* 10: 118-123, 2014.
36. Jacqmain M, Doucet E, Després JP, Bouchard C and Tremblay A: Calcium intake, body composition, and lipoprotein-lipid concentrations in adults. *Am J Clin Nutr* 77: 1448-1452, 2003.
37. Miyake S: The mechanism of release of hepatic enzymes in various liver diseases. II. Altered activity ratios of GOT to GPT in serum and liver of patients with liver diseases. *Acta Med Okayama* 33: 343-358, 1979.
38. Cremers J, Drent M, Driessen A, Nieman F, Wijnen P, Baughman R and Koek G: Liver-test abnormalities in sarcoidosis. *Eur J Gastroenterol Hepatol* 24: 17-24, 2012.
39. Morán-Salvador E, López-Parra M, García-Alonso V, Titos E, Martínez-Clemente M, González-Pérez A, López-Vicario C, Barak Y, Arroyo V and Clària J: Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. *FASEB J* 25: 2538-2550, 2011.
40. Deng Q, Li X, Fu S, Yin L, Zhang Y, Wang T, Wang J, Liu L, Yuan X, Sun G, *et al*: SREBP-1c gene silencing can decrease lipid deposits in bovine hepatocytes cultured in vitro. *Cell Physiol Biochem* 33: 1568-1578, 2014.
41. Chang XX, Yan HM, Xu Q, Xia MF, Bian H, Zhu TF and Gao X: The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-term high-fat diet. *Lipids Health Dis* 11: 86, 2012.
42. Benn T, Kim B, Park YK, Yang Y, Pham TX, Ku CS, Farruggia C, Harness E, Smyth JA and Lee JY: Polyphenol-rich blackcurrant extract exerts hypocholesterolaemic and hypoglycaemic effects in mice fed a diet containing high fat and cholesterol. *Br J Nutr* 113: 1697-1703, 2015.
43. Zhao Y, Peng L, Yang LC, Xu XD, Li WJ, Luo XM and Jin X: Wedelolactone regulates lipid metabolism and improves hepatic steatosis partly by AMPK Activation and Up-regulation of expression of PPARα/LPL and LDLR. *PLoS One* 10: e0132720, 2015.